Literature DB >> 27468715

Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.

Beatrice Rubin1, Daniela Regazzo2, Marco Redaelli3, Carla Mucignat3, Marilisa Citton4, Maurizio Iacobone4, Carla Scaroni2, Corrado Betterle2, Franco Mantero2, Ambrogio Fassina5, Raffaele Pezzani2, Marco Boscaro2.   

Abstract

β-catenin is a multifunctional protein; it is a key component of the Wnt signaling, and it plays a central role in cadherin-based adhesions. Cadherin loss promotes tumorigenesis by releasing membrane-bound β-catenin, hence stimulating Wnt signaling. Cadherins seem to be involved in tumor development, but these findings are limited in adrenocortical tumors (ACTs). The objective of this study was to evaluate alterations in key components of cadherin/catenin adhesion system and of Wnt pathway. This study included eight normal adrenal samples (NA) and 95 ACT: 24 adrenocortical carcinomas (ACCs) and 71 adrenocortical adenomas (ACAs). β-catenin mutations were evaluated by sequencing, and β-catenin and cadherin (E-cadherin and N-cadherin) expression was analyzed by quantitative reverse transcription PCR (qRT-PCR) and by immunohistochemistry (IHC). We identified 18 genetic alterations in β-catenin gene. qRT-PCR showed overexpression of β-catenin in 50 % of ACC (12/24) and in 48 % of ACA (21/44). IHC data were in accordance with qRT-PCR results: 47 % of ACC (7/15) and 33 % of ACA (11/33) showed increased cytoplasmic or nuclear β-catenin accumulation. N-cadherin downregulation has been found in 83 % of ACC (20/24) and in 59 % of ACA (26/44). Similar results were obtained by IHC: N-cadherin downregulation was observed in 100 % (15/15) of ACC and in 55 % (18/33) of ACA. β-catenin overexpression together with the aberrant expression of N-cadherin may play important role in ACT tumorigenesis. The study of differentially expressed genes (such as N-cadherin and β-catenin) may enhance our understanding of the biology of ACT and may contribute to the discovery of new diagnostic and prognostic tools.

Entities:  

Keywords:  Adrenocortical carcinomas; Adrenocortical tumors; N-cadherin; Wnt/beta-catenin signaling pathway

Mesh:

Substances:

Year:  2016        PMID: 27468715     DOI: 10.1007/s13277-016-5257-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  47 in total

Review 1.  The many ways of Wnt in cancer.

Authors:  Paul Polakis
Journal:  Curr Opin Genet Dev       Date:  2007-02       Impact factor: 5.578

2.  Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers.

Authors:  Sébastien Gaujoux; Stéphane Pinson; Anne-Paule Gimenez-Roqueplo; Laurence Amar; Bruno Ragazzon; Pierre Launay; Tchao Meatchi; Rossella Libé; Xavier Bertagna; Anne Audebourg; Jessica Zucman-Rossi; Frédérique Tissier; Jérôme Bertherat
Journal:  Clin Cancer Res       Date:  2010-10-26       Impact factor: 12.531

Review 3.  Structure and biochemistry of cadherins and catenins.

Authors:  Lawrence Shapiro; William I Weis
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-09       Impact factor: 10.005

Review 4.  Genetic aspects of adrenocortical tumours and hyperplasias.

Authors:  Tânia L Mazzuco; Julien Durand; Audrey Chapman; Jefferson Crespigio; Isabelle Bourdeau
Journal:  Clin Endocrinol (Oxf)       Date:  2012-07       Impact factor: 3.478

5.  Epigenetic disruption of the WNT/ß-catenin signaling pathway in human cancers.

Authors:  Ying Ying; Qian Tao
Journal:  Epigenetics       Date:  2009-07-01       Impact factor: 4.528

6.  Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.

Authors:  Frédérique Tissier; Catherine Cavard; Lionel Groussin; Karine Perlemoine; Gwladys Fumey; Anne-Marie Hagneré; Fernande René-Corail; Eric Jullian; Christine Gicquel; Xavier Bertagna; Marie-Cécile Vacher-Lavenu; Christine Perret; Jérôme Bertherat
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

7.  N-cadherin expression in adrenal tumors: upregulation in malignant pheochromocytoma and downregulation in adrenocortical carcinoma.

Authors:  Amir Khorram-Manesh; Håkan Ahlman; Svante Jansson; Ola Nilsson
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

Review 8.  Caught up in a Wnt storm: Wnt signaling in cancer.

Authors:  Rachel H Giles; Johan H van Es; Hans Clevers
Journal:  Biochim Biophys Acta       Date:  2003-06-05

Review 9.  Genetics and epigenetics of adrenocortical tumors.

Authors:  Antonio M Lerario; Andreas Moraitis; Gary D Hammer
Journal:  Mol Cell Endocrinol       Date:  2013-11-09       Impact factor: 4.102

10.  N-cadherin in neuroblastoma disease: expression and clinical significance.

Authors:  Tim Lammens; Katrien Swerts; Lara Derycke; Annemie De Craemer; Sara De Brouwer; Katleen De Preter; Nadine Van Roy; Jo Vandesompele; Frank Speleman; Jan Philippé; Yves Benoit; Klaus Beiske; Marc Bracke; Geneviève Laureys
Journal:  PLoS One       Date:  2012-02-15       Impact factor: 3.240

View more
  6 in total

1.  microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.

Authors:  Grace T Y Kwok; Jing Ting Zhao; Anthony R Glover; Anthony J Gill; Roderick Clifton-Bligh; Bruce G Robinson; Julian C Y Ip; Stan B Sidhu
Journal:  Oncologist       Date:  2019-03-27

Review 2.  Adrenocortical carcinoma: Pediatric aspects (Review).

Authors:  Florica Sandru; Răzvan-Cosmin Petca; Mara Carsote; Aida Petca; Mihai Cristian Dumitrascu; Adina Ghemigian
Journal:  Exp Ther Med       Date:  2022-02-16       Impact factor: 2.447

3.  β-Catenin-driven adrenocortical carcinoma is characterized with immune exclusion.

Authors:  Shenghua Liu; Guanxiong Ding; Zhongwen Zhou; Chenchen Feng
Journal:  Onco Targets Ther       Date:  2018-04-09       Impact factor: 4.147

4.  Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation.

Authors:  Wen Hui; Shenghua Liu; Jie Zheng; Zujun Fang; Qiang Ding; Chenchen Feng
Journal:  Cancer Med       Date:  2018-03-13       Impact factor: 4.452

Review 5.  The Role of Biomarkers in Adrenocortical Carcinoma: A Review of Current Evidence and Future Perspectives.

Authors:  Maja Mizdrak; Tina Tičinović Kurir; Joško Božić
Journal:  Biomedicines       Date:  2021-02-10

Review 6.  The human adrenal cortex: growth control and disorders.

Authors:  Claudimara Ferini Pacicco Lotfi; Jean Lucas Kremer; Barbara Dos Santos Passaia; Isadora Pontes Cavalcante
Journal:  Clinics (Sao Paulo)       Date:  2018-09-06       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.